Function of the endothelinB receptor in cardiovascular physiology and pathophysiology

Pharmacology and Therapeutics

Volumn 95, Issue 3, 2002, Pages 221-238

  D'Orleans Juste P ^a   Labonte J ^a   Bkaily, G ^a   Choufani, S ^a   Plante, M ^a   Honore J C ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Cardiovascular diseases; Endothelin 1; ETB receptors; Genetics; Nitric oxide; Pharmacological tools

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; ALPHA [[1 BUTYL 5 [2 [(2 CARBOXYPHENYL)METHOXY] 4 METHOXYPHENYL] 1H PYRAZOL 4 YL]METHYLENE] 6 METHOXY 1,3 BENZODIOXOLE 5 PROPANOIC ACID; BOSENTAN; BQ 238; BQ 928; ENDOTHELIN 1; ENDOTHELIN 1 [11-21]; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR AGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENRASENTAN; G PROTEIN COUPLED RECEPTOR; IRL 2500; L 744 743; L 744 753; MITOGEN ACTIVATED PROTEIN KINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; PROSTACYCLIN; PROTEIN TYROSINE KINASE; RES 701 1; RO 46 8443; SB 299670; STX S 6 C; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; DRUG INDUSTRY; ENDOTHELIUM CELL; HUMAN; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASCULAR SMOOTH MUSCLE;

EID: 0036710036     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00235-8     Document Type: Review

References (197)

1. Abe Y., Nakayama A., Yamanaka A., Sakurai T., Goto K. Subtype specific trafficking of endothelin receptors. J Biol Chem. 275:2000;8644-8671.
2. Allcock G.H., Battistini B., Fournier A., Warner T.D., Vane J.R. Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. J Pharmacol Exp Ther. 275:1995;120-126.
3. A receptor in endothelium of rabbit aortic valve. J Pharmacol Exp Ther. 271:1994;1359-1364.
4. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-732.
5. Arai H., Nakao K., Takaya K., Hosoda K., Ogawa Y., Nakanishi S., Imura H. The human endothelin-B receptor gene. Structural organization and chromosomal assignment. J Biol Chem. 268:1993;3463-3470.
6. B receptor antagonists. Br J Pharmacol. 120:1997;516-522.
7. Babaei S., Picard P., Ravandi A., Monge J.C., Lee T.C., Cernacek P., Stewart D.J. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res. 48:2000;158-167.
8. Balwierczak J.L., Bruseo C.W., DelGrande D., Jeng A.Y., Savage P., Shetty S.S. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500. J Cardiovasc Pharmacol. 26:1995;S393-S396.
9. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 95:1998;14367-14372.
10. Bauer M., Bauer I., Sonin N.V., Kresge N., Baveja R., Yokoyama Y., Harding D., Zhang J.X., Clemens M.G. Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver. Hepatology. 31:2000;937-947.
11. Belloni A.S., Rossi G.P., Andreis P.G., Neri G., Albertin G., Pessina A.C. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 27:1996;1153-1159.
12. Berthiaume N., Yanagisawz M., D'Orleans-Juste P. Contribution of endogenous endothelin-1 and endothelin-A-receptors to the hypertensive state of endothelin-B heterozygous (±) knockout mice. J Cardiovasc Pharmacol. 36:2000;S72-S74.
13. B receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension. 36:2000;1002-1007.
14. Bialecki R.A., Fisher C.S., Murdoch W.W., Barthlow H.G., Bertelsen D.L. Functional comparison of endothelin receptors in human and rat pulmonary artery smooth muscle. Am J Physiol. 272:1997;L211-L218.
15. Bogoni G., Rizzi A., Calo G., Campobasso C., D'Orleans-Juste P., Regoli D. Characterization of endothelin receptors in the human umbilical artery and vein. Br J Pharmacol. 119:1996;1600-1604.
16. Boulanger C.M., Luscher T.F. Differential effect of cyclic GMP on the release of endothelin-1 from cultured endothelial cells and intact porcine aorta. J Cardiovasc Pharmacol. 17:1991;S264-S266.
17. B receptors. FEBS Lett. 334:1993;210-214.
18. B receptor. FEBS Lett. 383:1996;37-41.
19. Brochu E., Lacasse S., Lariviere R., Kingma I., Grose J.H., Lebel M. Differential effects of endotholin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol. 10:1999;1440-1446.
20. B receptors in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-788. FEBS Lett. 396:1996;238-242.
21. Burke S.E., Nelson R.A., Lubbers N.L., Ford T.T., Fu K.I., Padley R.J., Wegner C.D., Cox B.F. Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine. J Cardiovasc Pharmacol. 35:2000;838-844.
22. Chareandee C., Herman W.H., Hricik D.E., Simonson M.S. Elevated endothelin-1 in tubular epithelium is associated with renal allograft rejection. Am J Kidney Dis. 36:2000;541-549.
23. Clavell A.L., Stingo A.J., Margulies K.B., Brandt R.R., Burnett J.C. Jr. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol. 268:1995;F455-F460.
24. Clement M.G., Albertini M. Differential release of prostacyclin and nitric oxide evoked from pulmonary and systemic vascular beds of the pig by endothelin. Prostaglandins Leukot Essent Fatty Acids. 55:1996;279-285.
25. Clozel M., Breu V., Gray G.A., Kalina B., Loffler B.M., Burri K., Cassal J.M., Hirth G., Muller M., Neidhart W., Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 270:1994;228-235.
26. Clozel M., Ramuz H., Clozel J.P., Breu V., Hess P., Loffler B.M., Coassolo P., Roux S. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 290:1999;840-846.
27. Coe Y., Haleen S.J., Welch K.M., Coceani F. The endothelin-A-receptor antagonist PD 180988 (CI-1034) selectively reverses the pulmonary vasoconstrictor response to hypoxia in the lamb. J Cardiovasc Phamacol. 36:2000;S331-S333.
28. B receptors in human vascular smooth muscle. J Cardiovasc Pharmacol. 22:1993;S22-S25.
29. Davenport A.P. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature. Pharmacol Rev. 54:2002;219-226.
30. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology XXIII, The angiotensin receptors. Pharmacol Rev. 52:2000;415-472.
31. De Gottardi A., Shaw S., Sagesser H., Reichen J. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats. J Hepatol. 33:2000;733-737.
32. De-Melo J.D., Tonussi C.R., D'Orléans-Juste P., Rae G.A. Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain. 77:1998;261-269.
33. Deng A.Y. Linkage analysis for blood pressure with rat chromosome 15 markers. Folia Biol (Praha). 44:1998;45-48.
34. de Nucci G., Thomas R., D'Orléans-Juste P., Antunes E., Walder C., Warner T.D., Vane J.R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 85:1988;9797-9800.
35. Doherty A.M., Cody W.L., He J.X., DePue P.L., Cheng X.M., Welch K.M., Flynn M.A., Reynolds E.E., LaDouceur D.M., Davis L.S., Keiser J.A., Haleen S.J. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol. 22:1993;S98-S102.
36. D'Orléans-Juste P., Bkaily G., Duval M., Labonté J., Plante M., Cournoyer G., Berthiaume N. Endothelins and the release of autacoids. Warner T.D. Endothelin and its Inhibitors. 2001;277-298 Springer-Verlag, New York.
37. Duchman S.M., Thohan V., Kalra D., Torre-Amione G. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol. 15:2000;136-140.
38. B receptors. J Appl Physiol. 81:1996;1510-1515.
39. Dupuis J., Schwab A.J., Simard A., Cernacek P., Stewart D.J., Goresky C.A. Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. Am J Physiol. 277:1999;G905-G914.
40. d'Uscio L.V., Barton M., Shaw S., Luscher T.F. Endothelin in atherosclerosis: importance of risk factors and therapeutic implications. J Cardiovasc Pharmacol. 35:2000;S55-S59.
41. 2+-mobilization. Mol Cell Biochem. 176:1997;29-33.
42. Elshourbagy N.A., Adamou J.E., Gagnon A.W., Wu H.L., Pullen M., Nambi P. Molecular characterization of a novel human endothelin receptor splice variant. J Biol Chem. 271:1996;25300-25307.
43. B receptor-mediated constriction in the renal microcirculation of rats. J Physiol. 497:1996;211-218.
44. Endo A., Ayusawa M., Minato M., Takada M., Takahashi S., Harada K. Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr. 160:2001;217-222.
45. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension. 36:2000;62-67.
46. Evans R.G., Madden A.C., Cotterill E. ET-receptor subtypes: roles in regional renal vascular actions of exogenous and endogenous endothelins in anesthetized rabbits. J Cardiovasc Pharmacol. 35:2000;677-685.
47. B receptors in fever induced by LPS (E. coli) in rats. Br J Pharmacol. 125:1998;542-548.
48. B) receptor-activated potentiation of cholinergic nerve-mediated contraction in human bronchus. Br J Pharmacol. 118:1996;1873-1874.
49. Filep J.G., Herman F., Battistini B., Chabrier P.E., Braquet P., Sirois P. Antiaggregatory and hypotensive effects of endothelin-1 in beagle dogs: role for prostacyclin. J Cardiovasc Pharmacol. 17:1991;S216-S218.
50. Forbes J.M., Hewitson T.D., Becker G.J., Jones C.L. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int. 59:2001;1333-1341.
51. Fujitani Y., Ueda H., Okada T., Urade Y., Karaki H. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta. J Pharmacol Exp Ther. 267:1993;683-689.
52. Fujitani Y., Trifilieff A., Tsuyuki S., Coyle A.J., Bertrand C. Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice. Am J Respir Crit Care Med. 155:1997;1890-1894.
53. B receptors in rats. Biochem Biophys Res Commun. 199:1994;1461-1465.
54. Garcia-Villalon A.L., Monge L., Fernandez N., Sanchez M.A., Martinez M.A., Gomez B., Dieguez G. Basal inhibitory action of endogenous endothelin on the sympathetic contraction in the isolated rat tail artery. Eur J Pharmacol. 384:1999;163-167.
55. Gellai M., Fletcher T., Pullen M., Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol. 271:1996;R254-R261.
56. Germain A.M., MacDonald P.C., Casey M.L. Endothelin receptor mRNAs in human fetal membranes, chorionic vessels, and decidua parietalis. Mol Cell Endocrinol. 132:1997;161-168.
57. Givertz M.M., Colucci W.S., LeJemtel T.H., Gottlieb S.S., Hare J.M., Slawsky M.T., Leier C.V., Loh E., Nicklas J.M., Lewis B.E. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 101:2000;2922-2927.
58. Gratton J.P., Maurice M.C., D'Orleans-Juste P. Characterization of endothelin receptors and endothelin-converting enzyme activity in the rabbit lung. J Cardiovasc Pharmacol. 26:1995;S88-S90.
59. B receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension. 30:1997;1204-1209.
60. B receptor blockade potentiates the pressor response to big endothelin-1 but not big endothelin-2 in the anesthetized rabbit. Hypertension. 35:2000;726-731.
61. B receptor antagonism during cold preservation in renal transplantation. Transplantation. 71:2001;619-627.
62. Hamroun D., Mathieu M.N., Chevillard C. Change of endothelin receptor subtype in the MEG-01 human megakaryoblastic cell line. Eur J Pharmacol. 344:1998;307-312.
63. B receptor-mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate-salt-induced hypertensive rats. Biol Pharm Bull. 21:1998;800-804.
64. Hay D.W., Henry P.J., Goldie R.G. Is endothelin a mediator in asthma? Am J Respir Crit Care Med. 154:1996;1594-1597.
65. B receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther. 292:2000;1153-1160.
66. Herman F., Magyar K., Chabrier P.E., Braquet P., Filep J. Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs. Br J Pharmacol. 98:1989;38-40.
67. Higashi T., Ishizaki T., Shigemori K., Yamamura T., Nakai T. Pharmacological characterization of endothelin-induced rat pulmonary arterial dilatation. Br J Pharmacol. 121:1997;782-786.
68. B receptors in isolated perfused rat liver. Eur J Pharmacol. 328:1997;175-182.
69. Hirata Y., Emori T., Eguchi S., Kanno K., Imai T., Ohta K., Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 91:1993;1367-1373.
70. Hirata Y., Hayakawa H., Suzuki E., Kimura K., Kikuchi K., Nagano T., Hirobe M., Omata M. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation. 91:1995;1229-1235.
71. B receptors. Hypertension. 35:2000;732-739.
72. A receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol. 11:2000;1498-1504.
73. Honoré J.C., Robert B., Vacher-Lavenv M.C., Chapron C., Breviller-Fouché M., Ferré F. Expression of endothelin receptors in human myometrium during pregnancy and in uterine leimyomas. J Cardiol Pharmacol. 36:2000;5386-5389.
74. Hosoda K., Hammer R.E., Richardson J.A., Baynash A.G., Cheung J.C., Giaid A., Yanagisawa M. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell. 79:1994;1267-1276.
75. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 86:1989;2863-2867.
76. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T., Nishikibe M., Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA. 91:1994;4892-4896.
77. Ishikawa A., Suzuki K., Fujita K. A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow. Urol Res. 27:1999;312-314.
78. Iwasaki H., Eguchi S., Ueno H., Marumo F., Hirata Y. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology. 140:1999;4659-4668.
79. Iwasaki T., Mihara S., Shimamura T., Kawakami M., Hayasaki-Kajiwara Y., Naya N., Fujimoto M., Nakajima M. Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist. J Cardiovasc Pharmacol. 34:1999;139-147.
80. Kahler J., Mendel S., Weckmuller J., Orzechowski H.D., Mittmann C., Koster R., Paul M., Meinertz T., Munzel T. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 32:2000;1429-1437.
81. Kamath P.S., Carpenter H.A., Lloyd R.V., McKusick M.A., Steers J.L., Nagorney D.M., Miller V.M. Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl. 6:2000;596-602.
82. Kanaide H. The effects of endothelin on vascular tonus. Braz J Med Biol Res. 28:1995;7-17.
83. B receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation. Eur J Pharmacol. 231:1993;371-374.
84. Karet F.E., Charnock-Jones D.S., Harrison-Woolrych M.L., O'Reilly G., Davenport A.P., Smith S.K. Quantification of mRNA in human tissue using fluorescent nested reverse-transcriptase polymerase chain reaction. Anal Biochem. 220:1994;384-390.
85. Kiowski W., Sutsch G. The role of endothelin receptor antagonists in the treatment of chronic heart failure. Curr Cardiol Rep. 3:2001;232-240.
86. B receptor and nitric oxide in cats. Neurosci Lett. 176:1994;157-160.
87. Kobayashi T., Miyauchi T., Iwasa S., Sakai S., Fan J., Nagata M., Goto K., Watanabe T. Corresponding distributions of increased endothelin-B receptor expression and increased endothelin-1 expression in the aorta of apolipoprotein E-deficient mice with advanced atherosclerosis. Pathol Int. 50:2000;929-936.
88. B endothelin receptor. Biochem Biophys Res Commun. 217:1995;354-362.
89. B receptor subtypes. J Cardiovasc Pharmacol. 34:1999;359-367.
90. Kuc R.E., Karet F.E., Davenport A.P. Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol. 26:1995;S373-S375.
91. Kuc R.E., Davenport A.P. Endothelin-A-receptors in human aorta and pulmonary arteries are downregulated in patients with cardiovascular disease: an adaptive response to increased levels of endothelin-1? J Cardiovasc Pharmacol. 36:2000;S377-S379.
92. Kusafuka T., Wang Y., Puri P. Novel mutations of the endothelin-B receptor gene in isolated patients with Hirschsprung's disease. Hum Mol Genet. 5:1996;347-349.
93. Labonté J., Bkaily G., D'Orleans-Juste P. Endothelin-B-receptors-dependent-inhibition of platelet aggregation in the CD-1 mouse. J Cardiovasc Pharmacol. 36:2000;S184-S186.
94. 2 receptors in ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse. Br J Pharmacol. 132:2001;934-940.
95. Lam H.C. Role of endothelin in diabetic vascular complications. Endocrine. 14:2001;277-284.
96. Langleben D., Barst R.J., Badesh D., Groves B.M., Tapson V.F., Murali S., Bourge R.C., Ettinger N., Shalit E., Clayton L.M., Jobsis M.M., Blackburn S.D., Crow J.W., Steward D.J., Long W. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 99:1999;3266-3271.
97. Lebel M., Moreau V., Grose J.H., Kingma I., Langlois S. Plasma and peritoneal endothelin levels and blood pressure in CAPD patients with or without erythropoietin replacement therapy. Clin Nephrol. 49:1998;313-318.
98. B receptors in human cirrhosis: relationship with hepatic hemodynamics. J Vasc Res. 35:1998;186-193.
99. Le Monnier de Gouville A.C., Lippton H., Cohen G., Cavero I., Human A. Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther. 254:1990;1024-1028.
100. Lewis K., Cadieux A., Rae G.A., Gratton J.P., D'Orleans-Juste P. Nitric oxide limits the eicosanoid-dependent bronchoconstriction and hypotension induced by endothelin-1 in the guinea-pig. Br J Pharmacol. 126:1999;93-102.
101. Lind H., Adner M., Erlinge D., Brunkwall J., Edvinsson L. Selective increase of the contractile response to endothelin-1 in subcutaneous arteries from patients with essential hypertension. Blood Press. 8:1999;9-15.
102. Lowbeer C., Ottosson-Seeberger A., Gustafsson S.A., Norrman R., Hulting J., Gutierrez A. Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. Nephrol Dial Transplant. 14:1999;1948-1955.
103. Luscher T.F., Richard V., Tschudi M., Yang Z.H., Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol. 15:1990;519-527.
104. Lysko P.G., Elshourbagy N.A., Pullen M., Nambi P. Developmental expression of endothelin receptors in cerebellar neurons differentiating in culture. Brain Res Dev Brain Res. 28:1995;96-101.
105. Mallat A., Fouassier L., Preaux A.M., Gal C.S., Raufaste D., Rosenbaum J., Dhumeaux D., Journeaux C., Mavier P., Lotersztajn S. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest. 96:1995;42-49.
106. Marazziti D., Golini E., Gallo A., Lombardi M.S., Matteoni R., Tocchini-Valentini G.P. Cloning of GPR37, a gene located on chromosome 7 encoding a putative G-protein-coupled peptide receptor, from a human frontal brain EST library. Genomics. 45:1997;68-77.
107. Masaki T., Vane J.R., Vanhoutte P.M. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev. 46:1994;137-142.
108. Mass J., D'Orléans-Juste P., Yano M., Rae G.A. Evidence for atypical endothelin receptors and for presence of endothelin-converting enzyme activity in the mouse isolated vas deferens. Eur J Pharmacol. 276:1995;113-121.
109. Matsumura Y., Hashimoto N., Taira S., Kuro T., Kitano R., Ohkita M., Opgenorth T.J., Takaoka M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension. 33:1999;759-765.
110. B receptor-mediated inhibitory actions on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. J Cardiovasc Pharmacol. 30:1997;325-331.
111. B receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit. Br J Pharmacol. 120:1997;319-325.
112. Mazzocchi G., Malendowicz L.K., Musajo F.G., Gottardo G., Markowska A., Nussdorfer G.G. Role of endothelins in regulation of vascular tone in the in situ perfused rat adrenals. Am J Physiol. 274:1998;E1-E5.
113. McLarnon J.G., Wang X., Bae J.H., Kim S.U. Endothelin-induced changes in intracellular calcium in human microglia. Neurosci Lett. 263:1999;9-12.
114. McMullan D.M., Bekker J.M., Johengen M.J., Hendricks-Munoz K., Gerrets R., Black S.M., Fineman J.R. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1. Am J Physiol Heart Circ Physiol. 280:2001;H777-H785.
115. McMurdo L., Lidbury P.S., Corder R., Thiemermann C., Vane J.R. Heterogeneous receptors mediate endothelin-1-induced changes in blood pressure, hematocrit, and platelet aggregation. J Cardiovasc Pharmacol. 22:1993;S185-S188.
116. B receptor. Br J Pharmacol. 109:1993;530-534.
117. B endothelin receptor antagonists. Bioorg Med Chem Lett. 9:1999;619-622.
118. Miasiro N., Karaki H., Paiva A.C. Distinct endothelin-B receptors mediate the effects of sarafotoxin S6c and IRL1620 in the ileum. J Cardiovasc Pharmacol. 31:1998;S175-S178.
119. B receptors in rat isolated small mesenteric arteries. Br J Pharmacol. 120:1997;1376-1382.
120. Minkes R.K., Kadowitz P.J. Hemodynamic responses to sarafotoxin 6 peptides. J Cardiovasc Pharmacol. 17:1991;S293-S296.
121. Mizuguchi T., Nishiyama M., Moroi K., Tanaka H., Saito T., Masuda Y., Masaki T., de Wit D., Yanagisawa M., Kimura S. Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin B receptor gene knockout mouse. Br J Pharmacol. 120:1997;1427-1430.
122. Modesti P.A., Vanni S., Paniccia R., Bandinelli B., Bertolozzi I., Polidori G., Sani G., Serneri G.G.N. Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes. J Cardiovasc Pharmacol. 34:1999;333-339.
123. Molenaar P., O'Reilly G., Sharkey A., Kuc R.E., Harding D.P., Plumpton C., Gresham G.A., Davenport A.P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 72:1993;526-538.
124. B receptor mRNA in human omental arteries after organ culture: quantification by competitive reverse transcription-polymerase chain reaction. Clin Exp Pharmacol Physiol. 25:1998;788-794.
125. B receptor mRNA in bronchial biopsies from patients with asthma and chronic airway obstruction. Eur J Pharmacol. 365:1999;R1-R3.
126. B receptors. Neuroreport. 8:1997;2127-2131.
127. A receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure. Circulation. 102:2000;188-193.
128. B-like receptors. Biochem Biophys Res Commun. 184:1992;100-106.
129. Morishita Y., Chiba S., Tsukuda E., Tanaka T., Ogawa T., Yamasaki M., Yoshida M., Kawamoto I., Matsuda Y. RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. I. Characterization of producing strain, fermentation, isolation, physico-chemical and biological properties. J Antibiot. 47:1994;269-275.
130. Mutafova-Yambolieva V.N., Westfall D.P. Inhibitory and facilitatory presynaptic effects of endothelin on sympathetic cotransmission in the rat isolated tail artery. Br J Pharmacol. 123:1998;136-142.
131. Nelson J.B., Carducci M.A. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. Br J Urol. 85:2000;45-48.
132. Nilsson T., Cantera L., Adner M., Edvinsson L. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries. Neurosurgery. 40:1997;346-351.
133. A receptors in endothelial cells in situ on the aortic side of porcine aortic valve. Br J Pharmacol. 115:1995;1369-1376.
134. Ohlstein E.H., Beck G.R. Jr., Douglas S.A., Nambi P., Lago M.A., Gleason J.G., Ruffolo R.R. Jr., Feuerstein G., Elliott J.D. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther. 271:1994;762-768.
135. Ohlstein E.H., Nambi P., Lago A., Hay D.W., Beck G., Fong K.L., Eddy E.P., Smith P., Ellens H., Elliott J.D. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther. 276:1996;609-615.
136. B receptor in mice. Am J Physiol. 276:1999;R1071-R1077.
137. B. Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes. J Biol Chem. 272:1997;21589-21596.
138. Oksche A., Boese G., Horstmeyer A., Furkert J., Beyermann M., Bienert M., Rosenthal W. Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol. 57:2000;1104-1113.
139. Ono N., Matsui T., Yoshida M., Suzuki-Kusaba M., Hisa H., Satoh S. Renal effects of endothelin in anesthetized rabbits. Eur J Pharmacol. 359:1998;177-184.
140. Orth S.R., Amann K., Gehlen F., Unger L., Wagner J., Raschack M., Ritz E. Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J Cardiovasc Pharmacol. 36(suppl. 1):2000;S232-S237.
141. B receptors couple to two distinct signalling pathways in porcine kidney epithelial LLC-PK1 cells. J Pharmacol Exp Ther. 270:1994;1035-1040.
142. B receptors counteract venoconstrictor effects of endothelin-1 in anesthetized rats. Life Sci. 63:1998;1239-1249.
143. Pang C.Y., Zhang J., Xu H., Lipa J.E., Forrest C.R., Neligan P.C. Role and mechanism of endothelin-B receptors in mediating ET-1-induced vasoconstriction in pig skin. Am J Physiol. 275:1998;R1066-R1074.
144. Pernow J., Bohm F., Johansson B.L., Hedin U., Ryden L. Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol. 36:2000;S418-S420.
145. A receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation of simultaneous
146. Porter K.E., Olojugba D.H., Masood I., Pemberton M., Bell P.R., London N.J. Endothelin B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg. 28:1998;697-701.
147. Pouzeratte Y., Grazzini E., Mathieu M.N., Iborras F., Guillon G., Chevillard C. Signaling mechanisms induced by endothelin agonists in human adrenal glomerulosa cells. J Cardiovasc Pharmacol. 31:1998;S501-S503.
148. Puffenberger E.G., Hosoda K., Washington S.S., Nakao K., deWit D., Yanagisawa M., Chakravarti A. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell. 79:1994;1257-1266.
149. Rabelink T.J., Kaasjager K.A., Boer P., Stroes E.G., Braam B., Koomans H.A. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 46:1994;376-381.
150. Rabelink T.J., Kaasjager K.A., Stroes E.S., Koomans H.A. Endothelin in renal pathophysiology: from experimental to therapeutic application. Kidney Int. 50:1996;1827-1833.
151. Randall M.D. Vascular activities of the endothelins. Pharmacol Ther. 50:1991;73-93.
152. Rockey D.C. Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Biochem Biophys Res Commun. 207:1995;725-731.
153. Rockey D.C., Chung J.J. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest. 98:1996;1381-1388.
154. B receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors. FEBS Lett. 361:1995;243-249.
155. Rossi G., Albertin G., Belloni A., Zanin L., Biasolo M.A., PrayerGaletti T., Bader M., Nussdorfer G.G., Palu G., Pessina A.C. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest. 94:1994;1226-1234.
156. Ry S.D., Andreassi M.G., Clerico A., Biagini A., Giannessi D. Endothelin-1, endothelin-1 receptors and cardiac natriuretic peptides in failing human heart. Life Sci. 68:2001;2715-2730.
157. B agonistic activity. Biochem Biophys Res Commun. 179:1991;286-292.
158. Saetrum O.O., Cantera L., Adner M., Edvinsson L. Endothelin-A and -B receptors in human coronary arteries and veins. Regul Pept. 63:1996;149-156.
159. B endothelin receptor. Biochem Biophys Res Commun. 178:1991;656-663.
160. Sakamoto A., Yanagisawa M., Sawamura T., Enoki T., Sakurai T., Nakao K., Toyo-oka T., Maseki T. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinB-selective antagonist and endothelinB-selective agonists. J Biol Chem. 268:1993;14656-14659.
161. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348:1990;732-735.
162. B-receptors. Acta Physiol Scand. 163:1998;227-234.
163. B blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol. 269:1995;L668-L672.
164. Schibler L., Vaiman D., Oustry A., Giraud-Delville C., Cribiu E.P. Comparative gene mapping: a fine-scale survey of chromosome rearrangements between ruminants and humans. Genome Res. 8:1998;901-915.
165. Schichiri M., Marumo F., Hirata Y. Endothelin-B receptor-mediated suppression of endothelial apoptosis. J Cardiovasc Pharmacol. 31:1998;S138-S141.
166. Schlapfer J., Gallagher D.S., Burzlaff J.D., Davis S.K., Taylor J.F., Womack J.E. Physical mapping of the endothelin receptor type B to bovine chromosome 12. Mamm Genome. 8:1997;380-381.
167. Schmitz-Spanke S., Schipke J. Potential role of endothelin-1 and endothelin antagonists in cardiovascular diseases. Basic Res Cardiol. 85:2000;290-298.
168. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 89:1994;1203-1208.
169. Shraga-Levine Z., Galron R., Sokolovsky M. Cyclic GMP formation in rat cerebellar slices is stimulated by endothelins via nitric oxide formation and sarafotoxins via formation of carbon monoxide. Biochemistry. 33:1994;14656-14659.
170. Shraga-Levine Z., Sokolovsky M. Functional coupling of G proteins to endothelin receptors is ligand and receptor subtype specific. Cell Mol Neurobiol. 20:2000;305-317.
171. Shyamala V., Moulthrop T.H., Stratton-Thomas J., Tekamp-Olson P. Two distinct human endothelin B receptors generated by alternative splicing from a single gene. Cell Mol Biol Res. 40:1994;285-296.
172. Smith P.J., Teichert-Kuliszewska K., Monge J.C., Stewart D.J. Regulation of endothelin-B receptor mRNA expression in human endothelial cells by cytokines and growth factors. J Cardiovasc Pharmacol. 31:1998;S158-S160.
173. Sokolovsky M. Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling. Pharmacol Ther. 54:1992;129-149.
174. Sokolovsky M., Ambar I., Galron R. A novel subtype of endothelin receptors. J Biol Chem. 267:1992;20551-20554.
175. Spieker L.E., Noll G., Ruschitzka F.T., Luscher T.F. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 37:2001;1493-1505.
176. Strachan F.E., Spratt J.C., Wilkinson I.B., Johnston N.R., Gray G.A., Webb D.J. Systemic blockade of the endothelin-B peripheral vascular resistance in healthy men. Hypertension. 33:1999;581-585.
177. Sun H.S., Wang L., Rothschild M.F., Tuggle C.K. Assignment of porcine serotonin receptor subtype 2 alpha and endothelin-B receptor to chromosome 11 by linkage analysis. J Anim Sci. 77:1999;795-796.
178. Syed N., Gulmi F.A., Chou S.Y., Mooppan U.M., Kim H. Renal actions of endothelin-1 under endothelin receptor blockade by BE-18257B. J Urol. 159:1998;563-566.
179. Syrris P., Carter N.D., Patton M.A. Novel nonsense mutation of the endothelin-B receptor gene in a family with Waardenburg-Hirschsprung disease. Am J Med Genet. 87:1999;69-71.
180. Takahashi H., Soma S., Muramatsu M., Oka M., Fukuchi Y. Upregulation of ET-1 and its receptors and remodeling in small pulmonary veins under hypoxic conditions. Am J Physiol Lung Cell Mol Physiol. 280:2001;L1104-L1114.
181. B receptor. Biochem Biophys Res Commun. 184:1992;953-959.
182. Tanaka H., Moroi K., Iwai J., Takahashi H., Ohnuma N., Hori S., Takimoto M., Nishiyama M., Masaki T., Yanagisawa M., Sekiya S., Kimura S. Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. J Biol Chem. 273:1998;11378-11383.
183. Terada Y., Tomita K., Nonoguchi H., Marumo F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest. 90:1992;107-112.
184. Torre-Amione G., Young J.B., Durand J., Bozhurt B., Mann D.L., Kobrin I., Pratt C.M. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, with class III to IV congestive heart failure. Circulation. 103:2001;973-980.
185. Tsuchiya K., Naruse M., Sanaka T., Naruse K., Zeng Z.P., Nitta K., Demura H., Shizume K., Sugino N. Renal and hemodynamic effects of endothelin in anesthetized dogs. Am J Hypertens. 3:1990;792-795.
186. B receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem. 269:1994;21778-21785.
187. Uhlhig S., Featherstone R.L. The interaction of endothelin receptor responses in the isolated perfused rat lung. Naunyn Schmiedebergs Arch Pharmacol. 356:1997;392-397.
188. 15]-endothelin-1(11-21). FEBS Lett. 311:1992;12-16.
189. Valdenaire O., Giller T., Breu V., Ardati A., Schweizer A., Richards J.G. A new family of orphan G protein-coupled receptors predominantly expressed in the brain. FEBS Lett. 424:1998;193-196.
190. Verhaar M.C., Strachan F.E., Newby D.E., Cruden N.L., Koomans H.A., Rabelink T.J., Webb D.J. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 97:1998;752-756.
191. B receptor antagonism during endotoxin shock. Eur J Pharmacol. 386:1999;235-245.
192. Warner T.D., Mitchell J.A., de Nucci G., Vane J.R. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol. 13:1989;S85-S88.
193. B receptor-mediated contraction in cultured segments of human temporal artery. Regul Pept. 81:1999;89-95.
194. 125I]-BQ3020 binding to rat cerebellar endothelin receptors. Br Pharmacol. 118:1996;2126-2130.
195. Williams D.L. Jr., Murphy K.L., Nolan N.A., O'Brien J.A., Lis E.V. Jr., Pettibone D.J., Clineschmidt B.V., Krause S.M., Veber D.F., Naylor E.M., Chakravart P.K., Walsh T.F., Dhanoa D.M., Chen A., Bagley S.W., Fitch K.J., Greenlee W.J. Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist. Life Sci. 58:1996;1149-1157.
196. Williamson D.J., Wallman L.L., Jones R., Keogh A.M., Scroope F., Penny R., Weber C., Macdonald P.S. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 102:2000;411-418.
197. Zimmermann M., Seifert V. Endothelin and subarachnoid hemorrhage - an overview. Neurosurgery. 43:1998;863-875.